PO:07:103 | Tocilizumab use in patients with rheumatoid arthritis and malignancy: a monocentric experience
Background. In 2024, the EULAR published a set of points to consider for initiating targeted therapy in rheumatoid arthritis (RA) patients with a history of malignancy, indicating TNF inhibitors are preferred in solid tumors, while rituximab is recommended for hematological malignancies. Although t...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
PAGEPress Publications
2025-11-01
|
| סדרה: | Reumatismo |
| נושאים: | |
| גישה מקוונת: | https://www.reumatismo.org/reuma/article/view/2021 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|